Lanreotide vs Orforglipron
Overview
Lanreotide is primarily a hormonal peptide, while Orforglipron is used for weight management & metabolic.
This page compares Lanreotide and Orforglipron across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Lanreotide | Orforglipron | |
|---|---|---|
| Category | Hormonal | Weight Management & Metabolic |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 60-120 mg | Clinical trials |
| Frequency | every 4 weeks | daily |
| Reported benefits | suppression of excess growth hormone and IGF-1 in acromegaly, improved progression-free survival in GEP-NETs, reduction of carcinoid syndrome symptoms, inhibition of multiple GI and pancreatic hormones | Oral administration convenience, weight loss, glucose control |
| Reported side effects | diarrhea, cholelithiasis, abdominal pain, hyperglycemia, bradycardia, injection site reactions, nausea, hypertension, headache, thyroid function decreases | Under investigation |
Key differences
Primary use. Lanreotide is categorised under Hormonal, while Orforglipron falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Lanreotide: FDA-approved. Orforglipron: FDA-approved.
Dosing. Lanreotide is typically dosed at 60-120 mg (every 4 weeks). Orforglipron is typically dosed at Clinical trials (daily).
Can you stack them?
Some protocols combine peptides, but stacking Lanreotide and Orforglipron has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Lanreotide and Orforglipron?
- Lanreotide is primarily a hormonal peptide, while Orforglipron is used for weight management & metabolic. Lanreotide is FDA-approved for one or more indications, whereas Orforglipron is FDA-approved for one or more indications.
- What is Lanreotide used for?
- FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome.
- What is Orforglipron used for?
- Oral GLP-1.
- Can you take Lanreotide and Orforglipron together?
- Some users combine peptides within a single protocol, but stacking Lanreotide and Orforglipron has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Lanreotide or Orforglipron FDA-approved?
- Lanreotide is FDA-approved for one or more indications. Orforglipron is FDA-approved for one or more indications.
Read the full articles
- Lanreotide — full monograph: mechanism, research, dosing & references
- Orforglipron — full monograph: mechanism, research, dosing & references